On December 25, 2020, orelabrutinib received approval from the China National Medical Products Administration in two indications: the treatment of patients with R/R chronic lymphocytic leukemia /small lymphocytic lymphoma, and the treatment of patients with R/R MCL.
At the end of 2021, orelabrutinib was included into National Reimbursement Drug List in China. In June 2021, orelabrutinib was granted as Breakthrough Therapy Designation for the treatment of R/R MCL by US Food and Drug Administration.
Mantle cell lymphoma is a unique subtype of B-cell non-Hodgkin's lymphoma, which is invasive and incurable, with increasing incidence rate year by year.
MCL is usually in the late stage when diagnosed, facing the challenges of limited treatment and poor prognosis.
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
On Dec. 25 2020, orelabrutinib received conditional approval from the China National Medical Products Administration in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia /small lymphocytic lymphoma, and the treatment of patients with relapsed/refractory mantle cell lymphoma.
At the end of 2021, orelabrutinib was included into National Reimbursement Drug list to benefit more lymphoma patients.
The supplemental New Drug Applications of orelabrutinib for the treatment of R/R WM and R/R Marginal Zone Lymphoma were accepted in China.
In addition to the approved indications, multi-center, multi-indication clinical trials are underway in the US and China with orelabrutinib as monotherapy or in combination therapies, such as first line treatment of MCD subtype of diffuse large B-cell lymphoma (DLBCL).
Orelabrutinib was granted as Breakthrough Therapy Designation for the treatment of r/r MCL by US Food and Drug Administration.
In addition, orelabrutinib is also being evaluated in global phase II studies for the treatment of Multiple Sclerosis, and clinical trials for the treatment of SLE, Primary Immune Thrombocytopenia and Neuromyelitis Optica Spectrum Disorder (NMOSD) in China.
InnoCare (HKEX: 09969) (SSE: 688428) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases.
It has a strategically focus on liquid cancer, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide.
InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong and the United States.
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data